camptothecin has been researched along with vildagliptin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Anikina, LV; Babkov, DA; Bezsonova, EN; Borisov, AV; Efremov, AM; Lozinskaya, NA; Perfilova, VN; Proskurnina, MV; Spasov, AA; Tsymlyakov, MD; Tyurenkov, IN; Zakharyascheva, OY; Zaryanova, EV | 1 |
2 other study(ies) available for camptothecin and vildagliptin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors.
Topics: A549 Cells; Animals; Binding Sites; Catalytic Domain; Cell Survival; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Glycogen Synthase Kinase 3 beta; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Oxindoles; Protein Kinase Inhibitors; Rats; Structure-Activity Relationship | 2019 |